Discovery and bioassay of disubstituted β-elemene-NO donor conjugates: synergistic enhancement in the treatment of leukemia / 中国天然药物
Chinese Journal of Natural Medicines (English Ed.)
;
(6): 916-926, 2023.
Article
Dans Anglais
| WPRIM
| ID: wpr-1011003
ABSTRACT
Natural products are essential sources of antitumor drugs. One such molecule, β-elemene, is a potent antitumor compound extracted from Curcuma wenyujin. In the present investigation, a series of novel 13,14-disubstituted nitric oxide (NO)-donor β-elemene derivatives were designed, with β-elemene as the foundational compound, and subsequently synthesized to evaluate their therapeutic potential against leukemia. Notably, the derivative labeled as compound 13d demonstrated a potent anti-proliferative activity against the K562 cell line, with a high NO release. In vivo studies indicated that compound 13d could effectively inhibit tumor growth, exhibiting no discernible toxic manifestations. Specifically, a significant tumor growth inhibition rate of 62.9% was observed in the K562 xenograft tumor mouse model. The accumulated data propound the potential therapeutic application of compound 13d in the management of leukemia.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Sesquiterpènes
/
Dosage biologique
/
Leucémies
/
Donneur d'oxyde nitrique
/
Lignée cellulaire tumorale
/
Prolifération cellulaire
Limites du sujet:
Animaux
/
Humains
langue:
Anglais
Texte intégral:
Chinese Journal of Natural Medicines (English Ed.)
Année:
2023
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS